NASDAQ / LIVE COMPANY INTELLIGENCE

Jade Biosciences, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERJBIO
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / JBIO COVERAGE

What’s moving Jade Biosciences, Inc. now

Current reporting with the operating signal separated from the noise.

01
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Investors are testing whether Jade Biosciences, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

The story matters when it changes Jade Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

The story matters when it changes Jade Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Jade Biosciences, Inc. to Participate in H.C. Wainwright and Stifel Biotech Investor Conferences

Jade Biosciences, Inc. to Participate in H.C. Wainwright and Stifel Biotech Investor Conferences

The development tests whether Jade Biosciences, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
05
Jade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and Innovation

Jade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and Innovation

The story matters when it changes Jade Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest JBIO filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-14 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-06 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-01 · Period 2026-06-29SEC ↗8-KMaterial company eventFiled 2026-06-26 · Period 2026-06-25SEC ↗8-KMaterial company eventFiled 2026-06-11 · Period 2026-06-08SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-09SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-17SEC ↗
EARNINGS / QUARTERLY TRACKER

Jade Biosciences, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.